NVO

NOVO NORDISK A S

Healthcare • CIK 0000353278

Loading...

Market Cap
—
P/E (TTM)
—
Rev Growth (TTM)
—
Net Margin (TTM)
—
FCF Yield (TTM)
—
FCF Margin (TTM)
—

What Changed

View Full Filings
20-F FY 2025 vs 20-F FY 2024
340B Drug Pricing Program Riskhigh (USD 4.2B revenue constrained as provision for...→low (HRSA dismissed ADR petition January 20, 2026; USD...
US GLP-1 and Insulin Net Pricesmedium (US payer rebate pressure increasing in insulin...→medium (average net prices after rebates for full Novo...
GLP-1 Volume Market Sharemedium (competitive pressure emerging in both obesity...→medium (volume market share lost in GLP-1 for both...
Akero Therapeutics Acquisitionno MASH clinical-stage asset in pipeline→acquired Akero Therapeutics at $54 per share (Phase 3...
Illicit GLP-1 Compoundingmedium (GLP-1 drug shortage permitting compounding...→medium (GLP-1 shortage resolved but illicit compounding...

Q1 2026 income statement: verify USD 4.2B 340B revenue recognized (look for...·GLP-1 volume market share in FY 2026 20-F: track whether obesity and diabetes...·US average net price trajectory: monitor rebate percentage trends across...

Filings your agent reads

Factsheet

Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.

6-KJun 20261 week agosource
6-KJun 20262 weeks agosource
6-KJun 20263 weeks agosource
6-KJun 20262026-06-01source
6-KMay 20262026-05-27source

Point your agent at NVO and it navigates these the same way — citing each number back to the filing.

Connect your agentSee agents at work

LATEST EARNINGS

No earnings in last 90 days

Check back after next 8-K filing

Cash Flow Health

Free Cash Flow0/8 positive
TTM$–
FCF Margin
TTM–
Sector: 0.0%
OCF Margin–
OCF/NI–
CapEx Coverage–
FCF Yield–
FCF Growth (2Y)–
Cash Conversion Cycle
–
View Latest Filing →View Full Cash Flow Statement →

Capital Allocation & Returns

Shareholder Friendly
Total Shareholder Yield
TTM22.9%

Strong capital returns to shareholders

Dividend & Payout Metrics
Dividend Yield (TTM)—
Shows how management rewards shareholders

Operational Efficiency & Returns

Return on Invested CapitalTTM
—
P25MedianP75
(med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
—
Asset Turnover
–
Leverage (1+D/E)
1.67x
D/E: 0.67x
Asset & CapEx Efficiency
Asset-based ROIC formula

Valuation Analysis

Price-to-EarningsTTM
–
Valuation Lenses
Earnings
–
vs – sector
Cash Flow
–
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: –
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap–
EV–
Multi-angle valuation analysis with sector context

Business Quality & Moat

Overall Quality Score
–/100
Unknown

Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)

Returns on Capital

Return on Equity (ROE)
–
8Q:–
Return on Invested Capital (ROIC)
–
8Q:–
vs Sector:-0.0%

Earnings Quality

Cash Conversion

–

OCF / Net Income

FCF Consistency

–

Positive quarters

Competitive Moat Indicators

Pricing Power

Gross Margin–

Capital Efficiency

Invested Capital Turnover–

Working Capital

Cash Conversion Cycle–

Growth Quality & Momentum

Growth Rates

Revenue Growth YoY
N/A
OpInc Growth YoY
N/A
EPS Growth YoY
N/A
FCF 3Y CAGR
N/A

Margin Quality & Sustainability

Moderate
Profitability Cascade
Gross
—
Operating
—
Net
—
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
—
FCF: — | Net: —

Quality = stability + cash conversion + low dilution

Balance Sheet & Solvency

Adequate
Net Debt / EBITDA
–Net Debt: $104.49B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.67x
Balance sheet risk & solvency analysis

Research

All research